Saturday, November 23, 2024
11/23/2024
Summary Interleukin-17 (IL-17), a pro-inflammatory cytokine, is pathogenic in autoimmune diseases such as Inflammatory Arthritis (IA). IA affects more than 1% of the worldwide population and remains incurable to date1. Ectopic IL17A expression in mice induces IA phenotype and provides a model to study mechanisms2. Activation of IL-17A receptor (IL-17R) recruits a signaling complex consisting of Act1 and TRAFs (Tumor Necrosis Factor Receptor Associated Factors). Activation of TRAF6 or TRAF2/5 results in transcriptional (IL6) and post- transcriptional (CXCL1) outcomes of IL-17A cytokine. TRAFs often interact with each other and influence signaling outcomes. The crosstalk between the TRAF6 and TRAF2/5 branches in IL-17A signaling remains unknown. Our recent PNAS publications showed that 14-3-3z is a novel component of IL-17R signaling and suppresses IA. In IL-17A signaling, 14-3-3z connects the two TRAF branches, inhibits TRAF5 but promotes TRAF6. There are two motifs on 14-3-3z that interact and show specificity to TRAF5 and TRAF6 binding. We also showed that TRAF5 inhibits TRAF6-dependent IL-17A signaling. Our new preliminary data show that 14- 3-3z modifies TRAFs and their interactions with other cellular proteins, thus providing clues to its mechanism. Our long-term goal is to understand how 14-3-3z bridges TRAFs in IL-17R signaling and diseases. We hypothesize that “14-3-3z has a dual role in IL-17 signaling by executing the opposing functions of TRAFs, leading to the prevention of IA.” We propose to investigate the molecular mechanisms and physiological relevance of the 14-3-3z-TRAF axis in regulating IL-17R signaling and inflammatory arthritis with three specific aims. The first two aims will examine how 14-3-3z regulates TRAF5 and TRAF6 activity, connects two branches, and gain an in-depth understanding of 14-3-3z’s function in IL-17R signaling. In the third aim, we will examine the physiological relevance of the 14-3-3z-TRAF axis using an innovative IL-17A gene transfer model to study 14-3-3z role in chronic IL-17A and IA pathogenesis using 14-3-3z knockout animals. Successful completion of this proposal will provide mechanistic insight into how 14-3-3z modifies TRAF proteins and their activity, regulates IL-17R signaling, and suppresses IA. This study is innovative because by studying 14-3-3z’s role in TRAF biology, we examine the molecular basis of a novel fundamental immune regulatory axis in IL-17R signaling and IA. Our study is significant because understanding 14-3-3z action on TRAFs advances our fundamental knowledge of protein biochemistry, immunology, IL-17R signaling, IA pathogenesis, and other autoimmune diseases. IA is a challenging disease with limited therapeutic options; therefore, a deeper understanding of IA pathogenesis is desired. And, as TRAFs play a critical role in many receptor signaling, the implications of 14-3-3z functions go beyond IL-17R signaling to many other autoimmune and infectious diseases.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
